Vol 3 No 1: 2006...2009: Now we know T-cell lymphomas better, Bologna, Italy, 16-18 March 2009
2006...2009: Now we know T-cell lymphomas better, Bologna, Italy, 16-18 March 2009

Articles

E.S. Jaffe
T-cell and natural killer-cell lymphomas An update based on the 2008 WHO classification
PDF
D. Sibon
First line therapy for peripheral T-cell lymphoma
PDF
R Liang
Treatment of natural killer/T-cell lymphoma
PDF
BD Cheson
The role of positron emission tomography in T-cell lymphoma and T-cell specific response criteria
PDF
M Duvic
Epigenetic approaches. Histone deacetylase inhibitors: vorinostat. A new treatment option for advanced cutaneous T-cell lymphoma
PDF
HM Prince, M Prince
Panobinostat (LBH589): a novel pan-deacetylase inhibitor with activity in T cell lymphoma
PDF
F Foss, R Advani, K Hymes, B Pohlman, E Jacobsen, J McDonnell, A Lerner
Activity of Belinostat in patients with recurrent or refractory peripheral or cutaneous T-cell lymphoma
PDF
PP Piccaluga, M Rossi, A Gazzola, MR Sapienza, C Mannu, S Righi, C Agostinelli, MT Sista, SA Pileri
Gene expression profiling of peripheral T-cell lymphoma: from bench to bedside
PDF
P Gaulard, Y-L Huang, C Thielen, L de Leval
Angioimmunoblastic T-cell lymphoma: a tumor of follicular helper T cells derivation with clinical and pathological relevance
PDF
G Delsol, L Brugières, P Gaulard, E Espinos, L Lamant
Anaplastic large cell lymphoma, ALK-positive and anaplastic large cell lymphoma ALK-negative
PDF
C Ferme, MV Mateos, S Szyldergemajn, E Zucca, S Extremera, J Briones, G Alessandro, V Ribrag
Plitidepsin is active in peripheral T-cell lymphoma: a subset analysis from an ongoing multicenter phase II trial
PDF
JE Janik, D O’Mahony, TA Waldmann, JC Morris
Monoclonal antibody therapy of T cell lymphoma: single agent trials of anti-CD2 (Siplizumab) and anti-CD4 (Humax-CD4)
PDF
O Shonukan, AH Dantzig, S Kloeker-Rhoades, I Garcia-Ribas
Development of LY2334737, an oral gemcitabine prodrug for continuous administration. Perspectives for the therapy of mature T-cell and NK-cell lymphomas
PDF
V Gandhi
Forodesine
PDF
C Dearden
Pentostatin in peripheral T-cell lymphomas
PDF
N Schuelper, B Chapuy, T Relander, L Truemper, G Wulf
Preclinical evaluation of sorafenib against B- and T-cell lymphoma
PDF
R Advani
Immune modulation as a treatment strategy in angioimmunoblastic T-cell lymphoma
PDF
M Santucci
M. Santucci Cutaneous T-cell lymphomas: histology
PDF
MB Wozniak, SM Rodriguez Pinilla, R Villuendas, M Herrera, PL Ortiz, MA Piris
Cutaneous T-cell lymphoma, new insights
PDF
YH Kim
Zanolimumab (Humax-CD4), a fully human monoclonal antibody with significant clinical responses in cutaneous T-cell lymphoma
PDF
EA Olsen
Forodesine
PDF
M Tani, L Alinari, A Broccoli, E Derenzini, M Fina, L Gandolfi, E Marchi, C Pellegrini, V Stefoni, F Venturini, PL Zinzani
Gemcitabine
PDF
S Pulini, S Rupoli, G Goteri, R Alterini, M Cantonetti, A Fabbri, P Quaglino, N Pimpinelli
Pegylated, liposomal doxorubicin in the treatment of primary cutaneous T-cell lymphoma: an update
PDF
M Duvic
Innovative treatments: bexarotene
PDF
PL Zinzani
Innovative treatments: bortezomib
PDF
C Querfeld, TM Kuzel, J Guitart, ST Rosen
Lenalidomide (Revlimid®) in patients with cutaneous T-cell lymphoma
PDF
V Tosello, A Ferrando
NOTCH1: a therapeutic target for T cell acute lymphoblastic leukemia/lymphoma
PDF
A Pession, R Masetti, R Rondelli
Pediatric T-cell acute lymphoblastic leukemia and T-cell lymphoblastic lymphoma therapy
PDF
M Bonifacio, O Perbellini, G Pizzolo
T-cell acute lymphoblastic leukemia and T-cell lymphoblastic lymphoma: therapy in adults
PDF
R Willemze
Prognostic factors in cutaneous T-cell lymphoma
PDF
P Reimer
High-dose therapy and autotransplantation in peripheral T-cell lymphoma and cutaneous T-cell lymphoma
PDF
P Corradini, A Dodero, G Lambertenghi-Deliliers, F Onida
Allogeneic transplantation for peripheral and cutaneous T-cell lymphomas
PDF